Shares of EyePoint Pharmaceuticals EYPT moved lower by 2.5% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 9.09% year over year to ($0.10), which were in line with the estimate of ($0.10).
Revenue of $4,122,000 decreased by 42.83% from the same period last year, which beat the estimate of $3,730,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Aug 05, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/jnqtvad7
Technicals
52-week high: $2.69
52-week low: $0.66
Price action over last quarter: down 13.34%
Company Overview
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed 5 FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
